Low‐dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives
International Journal of Cancer · 2024-04 · 154 (7) · 1143-1157
DOI: 10.1002/ijc.34801 ↗At a glance
Übersichtsarbeit in International Journal of Cancer, published online on 2023-12-07. Written by Laiyan Zhou and 6 co-authors. Institution: Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Major MEDLINE topics: Neoplasms. Cited 31 times so far (Crossref); 154 references. Funded by: Bethune · Cancer Radiotherapy Translational Medicine Research Foundation, National Natural Science Foundation of China, The 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
Abstract (original language)
Radiotherapy has unique immunostimulatory and immunosuppressive effects. Although high‐dose radiotherapy has been found to have systemic antitumor effects, clinically significant abscopal effects were uncommon on the basis of irradiating single lesion. Low‐dose radiation therapy (LDRT) emerges as a novel approach to enhance the antitumor immune response due to its role as a leverage to reshape the tumor immune microenvironment (TIME). In this article, from bench to bedside, we reviewed the possible immunomodulatory role of LDRT on TIME and systemic tumor immune environment, and outlined preclinical evidence and clinical application. We also discussed the current challenges when LDRT is used as a combination therapy, including the optimal dose, fraction, frequency, and combination of drugs. The advantage of low toxicity makes LDRT potential to be applied in multiple lesions to amplify antitumor immune response in polymetastatic disease, and its intersection with other disciplines might also make it a direction for radiotherapy‐combined modalities.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Disaster Medical Center, Sichuan University, Chengdu, China.
- Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
- Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China.
ORCID profiles: Jianxin Xue
Funding
- Bethune · Cancer Radiotherapy Translational Medicine Research Foundation
- National Natural Science Foundation of China
- The 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
- The Outstanding Youth Talent Foundation for Science and Technology of Sichuan Province
Cite
APA
Zhou, L., Liu, Y., Wu, Y., Yang, X., Spring Kong, F. M., Lu, Y., & Xue, J. (2024). Low‐dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives. International Journal of Cancer, 154(7), 1143-1157. https://doi.org/10.1002/ijc.34801
Vancouver
Zhou L, Liu Y, Wu Y, Yang X, Spring Kong FM, Lu Y, et al. Low‐dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives. International Journal of Cancer. 2024;154(7):1143-1157. doi:10.1002/ijc.34801
BibTeX
@article{Zhou2024,
author = {Zhou, Laiyan and Liu, Yuanxin and Wu, Yuanjun and Yang, Xue and Spring Kong, Feng-Ming and Lu, You and Xue, Jianxin},
title = {Low‐dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives},
journal = {International Journal of Cancer},
year = {2024},
volume = {154},
number = {7},
pages = {1143--1157},
doi = {10.1002/ijc.34801}
}
EUVIMED